21:56 , Jun 28, 2019 |  BC Extra  |  Clinical News

June 28 Clinical Quick Takes: Imfinzi extends survival in Phase III SCLC study; plus LSK, Pfizer, FibroGen, Aclaris and more

AZ's Imfinzi shows survival benefit in Phase III for SCLC  AstraZeneca plc (LSE:AZN; NYSE:AZN) said an interim analysis of the Phase III CASPIAN trial showed Imfinzi plus etoposide and platinum-based chemotherapy met the primary endpoint...
19:05 , Jun 6, 2018 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Amyotrophic lateral sclerosis (ALS) Cell culture studies suggest activating NFE2L2 could help treat ALS by promoting normal folding of mutant SOD1. Crystallographic analyses of an ALS-associated SOD1 mutant complexed with a library of cysteine-reactive...
23:27 , Nov 30, 2017 |  BC Week In Review  |  Clinical News

Sound reports Phase Ib data for SPI-1005 in Meniere's disease

In October, Sound Pharmaceuticals Inc. (Seattle, Wash.) reported top-line data from a Phase Ib trial in 40 patients with Meniere’s disease showing that oral ebselen (SPI-1005) for 21 days improved low frequency hearing in 55%...
16:54 , Oct 6, 2017 |  BC Week In Review  |  Clinical News

Sound begins Phase IIb of SPI-1005 for Meniere's disease

Sound Pharmaceuticals Inc. (Seattle, Wash.) began the double-blind, placebo-controlled Phase IIb SPI-1005-251 trial of ebselen (SPI-1005) for 28 days in 120 patients with Meniere's disease. The trial will evaluate safety and include assessments of hearing...
19:41 , Jun 2, 2017 |  BioCentury  |  Product Development

Ears wide open

Based on unmet need alone, hearing loss should have been every bit as attractive to investors and drug developers as ophthalmic diseases, which entered a renaissance in the mid-2000s resulting in a multibillion-dollar market for...
08:00 , Jan 25, 2016 |  BC Week In Review  |  Clinical News

Ebselen: Phase Ib started

Sound began a double-blind, placebo-controlled, U.S. Phase Ib trial to evaluate 200, 400 and 600 mg oral SPI-1005 twice daily for 21 days in about 40 patients. Sound Pharmaceuticals Inc. , Seattle, Wash.   Product:...
07:00 , Oct 15, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Clostridium difficile toxin B (TcdB)

Infectious disease INDICATION: Clostridium In vitro and mouse studies suggest ebselen could be repurposed to treat Clostridium difficile infection (CDI). Screening of a small molecule library in an assay for binding to the cysteine protease...
07:00 , Aug 13, 2015 |  BC Innovations  |  Tools & Techniques

Helping Beethoven hear

Little progress has been made in developing therapies for hearing loss that go beyond the temporary and partial solutions provided by hearing aids and cochlear implants, and most company activity is focused on acquired forms...
08:00 , Feb 26, 2015 |  BC Innovations  |  Translation in Brief

Hearing after cisplatin

One fairly common consequence of platinum-based chemotherapy in children is loss of hearing, which occurs in up to 70% of pediatric patients who receive high doses of cisplatin. For many of them, the cause might...
07:00 , Sep 29, 2014 |  BioCentury  |  Emerging Company Profile

Oricula: Preserving hearing

Oricula Therapeutics LLC is developing a small molecule from the University of Washington to prevent hearing loss in patients treated with aminoglycoside antibiotics. The small molecule could allow expanded use of the antibiotics, which are...